PetMedix enters into partnership with Boehringer Ingelheim
Boehringer Ingelheim has entered into a partnership with PetMedix, a UK based research and development stage biopharmaceutical company.
Strengthening partnerships to accelerate innovation and growth is now one of the key elements of Boehringer Ingelheim’s refocused strategy.
Ingelheim, Germany, January 12, 2021 – Boehringer Ingelheim is pleased to announce a multi-year partnership with PetMedix to develop novel and transformative companion animal antibody therapeutics using PetMedix’s proprietary Ky9™ platform. As part of the collaboration, PetMedix will undertake discovery activities against a number of key targets, and Boehringer Ingelheim will work to develop and bring these therapies to market.
While there are many technologies that have been used to develop human therapeutic antibodies, PetMedix’s breakthrough approach is equivalent to one that has resulted in a number of successful, novel therapies for humans. PetMedix is the only company in the world that has brought this innovative approach to veterinary medicine, with its Ky9™ platform able to rapidly and efficiently generate fully canine therapeutic antibodies. This approach saves time and money in drug development, and reduces the risk of certain key adverse events relative to other antibody technologies.
Dr Tom Weaver, CEO of PetMedix, said
We are excited to be working with Boehringer Ingelheim on this project as we feel we bring complementary experience and expertise to this partnership. PetMedix has developed the leading pet antibody discovery engine, and it will be through Boehringer Ingelheim’s global scale and industry leadership that these novel therapies will best be able to succeed and ultimately benefit the animals
James Allan, Global Head of Transaction, Business Development & Licensing, Boehringer Ingelheim Animal Health, said:
Boehringer Ingelheim is pleased to be working with PetMedix on this cutting edge technology as a means to bring innovative new therapies to improve the health of animals globally. PetMedix has a unique expertise and its focus on innovation aligns well with our own